RxDoctor Payments Data

Babak Haddadian, MD

Interventional Cardiology · Milwaukee, WINPI 1801070487

Payments from drug & device makers

$3,119in general payments, 2019–2025

Across 23 payments — averaging $135.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Medtronic$194
  • AstraZeneca$179
  • Abbott$130
  • Surmodics, Inc.$117
  • Shockwave Medical, Inc$111
  • plus $123 from 2 others

What the payments were for

  • Travel & lodging$1,20939%
  • Food & beverage$1,73156%
  • Education$1796%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,119 in reported general payments places this provider in the 35th percentile of 118 interventional cardiology providers in Wisconsin.

See all interventional cardiology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$210,844
Medicare patients
884
Services billed
4,681

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban648$686,271
JardianceEmpagliflozin384$466,729
VyndamaxTafamidis12$290,144
EntrestoSacubitril/Valsartan193$251,594
Repatha SureclickEvolocumab188$138,935
XareltoRivaroxaban69$108,785
BrilintaTicagrelor110$103,972
VascepaIcosapent Ethyl59$26,977
Praluent PenAlirocumab33$15,384
LivaloPitavastatin Calcium33$14,898
Ranolazine ErRanolazine83$10,660
NexletolBempedoic Acid12$8,586
Atorvastatin Calcium1,016$8,447
Metoprolol Succinate744$8,191
Ezetimibe469$5,818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta$179$103,972110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 118 interventional cardiology providers in Wisconsin.

Other interventional cardiology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →